Relevant to AT1 ( AFR As well as COVID-19 rapid tests, the...

Relevant to AT1
( AFR As well as COVID-19 rapid tests, the company produces a world-first finger-prick blood test called FebriDx, which can indicate within 10 minutes if a person has a bacterial infection. It also makes a dual rapid test for influenza and COVID-19, which it plans to also bring to Australia.

Its new local manufacturing facility will also be able to produce tests spanning tropical diseases, influenza, sexually transmitted disease, and chronic diseases.It will be able to manufacture tests made not just by Lumos, but other diagnostics innovators.“Being able to scale up production so quickly shows the strength of Victoria’s advanced manufacturing capabilities,” Victorian Premier Daniel Andrews said.

Link https://www.copyright link/companies/healthcare-and-fitness/lumos-set-to-make-covid-19-rapid-tests-in-victoria-shares-soar-20220202-p59t8a

My question is, how does the leadership of Atomo look after announcing in the press that the Australian government were not ready to back such a facility. Several days later it happened. Do they not look a little foolish?

Secondly, LDX rose a trifling 8% after this announcement.Hardly 'soaring'.
It was listed at $1.25 and it's still only around a dollar. Baffling.

Same really with AT1's share price. What's really holding this share back? Is the technology just too knew and people can't figure it out?
If AT1 continues at this rate, in 4-5 years or so it will be bringing in 50-60 million dollars a year.